Europe Cannabidiol Market (2026 - 2033) Size, Share & Trends Analysis Report By Source (Hemp Derived CBD, Marijuana Derived CBD), By Product, Pharmaceutical-grade CBD), By Application, By Formulation, By Distribution Channel, By Country, And Segment Forecasts

Europe Cannabidiol Market Summary

Growing consumer awareness of the therapeutic and wellness benefits of CBD, particularly for managing anxiety, pain, and sleep disorders, is also accelerating adoption across both medical and recreational segments.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The section below outlines the key drivers shaping the cannabidiol market, including advancements in research and development and evolving industry trends. It highlights how increasing legalization, along with rising consumer interest in cannabidiol-based products, is contributing to overall market growth.

Growing legalization and harmonization of cannabidiol regulations across Europe

The European CBD market is advancing through broader legalization efforts and increasing alignment of national regulations. Europe is steadily progressing toward a more consistent and structured regulatory landscape for cannabidiol (CBD) products. In September 2025, the European Union Drugs Agency (EUDA) launched the Cannapol Toolkit, a three-year initiative designed to support member states in creating evidence-based frameworks for adult-use cannabis regulation. The program focuses on harmonizing national policies, advancing harm-reduction strategies, and enabling consistent data collection as countries such as Germany, the Netherlands, and Malta move forward with legal cannabis reforms.

Key regulatory developments across Europe

• EU Novel Food Regulation: CBD extracts intended for ingestion are classified as “novel foods,” requiring pre-market authorization to ensure safety, which has created a more structured but stringent approval pathway across EU countries.

• THC limits: Most European countries permit CBD products only if tetrahydrocannabinol (THC) content remains below 0.2%-0.3%, ensuring non-psychoactive use.

• Cosmetics & wellness segment: CBD is widely permitted in cosmetic applications under EU regulations, supporting strong growth in skincare and personal care segments.

• Country-level variations:

• Germany: Advancing regulated cannabis access and expanding medical cannabis frameworks.

• Netherlands: Continuing pilot programs for regulated cannabis supply chains.

• Malta: Among the first EU countries to legalize limited personal cannabis use and support non-profit cannabis associations.

• France & Italy: Allow CBD sales with strict THC limits and evolving clarity on product formats such as edibles and flowers.

To learn more about this report, Download Free Sample Report

Rising cross-border imports and exports shaping European CBD supply chains

The European cannabidiol and broader cannabis market is increasingly driven by expanding cross-border trade, as demand continues to outpace domestic production across key markets. Europe remains highly import-dependent, particularly for medical cannabis and CBD inputs, with Germany serving as the primary demand hub. In Q1-Q3 2024 alone, Germany imported approximately 39.8 tons of medical cannabis, with nearly 48% sourced from Canada, followed by Portugal and Denmark, highlighting a concentrated supplier base.

To learn more about this report, Download Free Sample Report

The broader European trends indicate that imports are rising rapidly due to a structural supply-demand gap, where patient demand and legalization are advancing faster than domestic cultivation infrastructure. This has led to increased international trade flows, improved logistics networks, and stronger regulatory alignment for pharmaceutical-grade cannabis and CBD products. 

Increasing medical use for pain, anxiety, and sleep-related conditions

The therapeutic benefits of cannabidiol have encouraged consumers to buy these products, despite their high cost. The commercial retailers are shifting their focus to selling cannabis-based items that yield higher profits. For instance, a report published by Nature Medicine in September 2025 highlights that an experimental cannabis extract reduced low back pain in a randomized, placebo-controlled trial in Europe, and Canadian doctors say it's the type of well-designed study they'll need to guide patients seeking safer medication options. 

Europe has witnessed a steady rise in medical cannabis registered patients across key markets such as Germany, Italy, and the UK as of 2024, many of whom use CBD-dominant formulations for therapeutic purposes. Germany alone accounts for a significant share, driven by reimbursement support for certain indications.

To learn more about this report, Download Free Sample Report

This growing evidence base is encouraging both physicians and patients to consider CBD as a complementary or alternative therapy, thereby strengthening demand despite relatively higher product costs. Retailers are increasingly prioritizing cannabis-based products due to their higher margins compared to traditional wellness supplements, further supporting market penetration.

Expanding retail and online distribution across European markets

The rapid growth of e-commerce and direct-to-consumer (D2C) channels has transformed distribution dynamics. Online platforms allow companies to reach a wider audience across borders, offer a diverse product portfolio, and provide discreet purchasing options, an important factor for first-time or health-conscious users.

To learn more about this report, Download Free Sample Report

The increasing penetration of internet-based retail has made online sales one of the fastest-growing segments within the market, supported by improved logistics and cross-border trade within the European Union.

Key Insights

• E-commerce leads CBD sales, accounting for nearly half (or more) of total sales in most countries, driven by convenience and product variety.

• Modern trade channels (supermarkets/hypermarkets) are gaining traction, especially in Spain and Germany.

• Channel fragmentation in CBD reflects its positioning as a wellness/lifestyle product rather than a strictly medical one.

Growing Use of Cannabis by Young People in the Region

Rising cannabis use among young people in Europe is contributing to increased demand for both recreational and CBD products, driven by greater social acceptance, lifestyle trends, and exposure through digital platforms. This demographic shift is encouraging companies to develop youth-oriented formats such as edibles, beverages, and wellness products, further supporting market growth.

To learn more about this report, Download Free Sample Report

A report published in October 2025 by the European Union Drugs Agency highlighted cannabis use among young adults in 2024, indicating that approximately 15.4% of young adults in Europe consumed cannabis. Country-wise data further shows notable variations across the region, reflecting differences in regulatory environments, cultural acceptance, and accessibility among young Europeans.

Market Concentration & Characteristics

The chart below represents the relationship between industry concentration, industry characteristics, and industry participants. There is a moderately high degree of innovation, a moderate level of merger & acquisition activities, a moderate impact of regulations, and moderate regional expansion.

The industry is moderately concentrated, with many players entering the market and launching new innovative products. The degree of innovation is medium, and the level of merger & acquisitions activities is medium. The impact of regulations on the market is moderate, and the regional expansion is low.

To learn more about this report, Download Free Sample Report

The degree of innovation is moderately high as both established companies and new entrants continuously introduce advanced formulations, delivery formats, and product applications. Innovation is particularly visible in areas such as nano-emulsified cannabidiol (CBD) for enhanced bioavailability and functional wellness products. For instance, in December 2025, Aurora expanded its leading portfolio of high-potency medical flower products in Poland. 

The industry is also marked by a moderate number of mergers and acquisitions (M&A) activities among the top players. These M&A activities allow companies to broaden their range of products, venture into new markets, and consolidate their position in the market. For instance, in February 2026, Canada’s Organigram Holdings Inc. announced a definitive agreement to acquire Germany’s Sanity Group for approximately USD 125.5 million to accelerate European market expansion.

“With a headline valuation of 250 million euros, this transaction is, to our knowledge, one of the largest of its kind, both within the German start-up scene and the European cannabis industry, particularly in the healthcare sector,”

-Finn Hänsel, founder and CEO of the Sanity Group.

The industry is growing due to an increasing number of nations establishing a structured regulatory system for the growth and sale of cannabis. For instance, according to the cannabis laws in Germany, CBD products should not exceed a THC content of 0.2% and must be sold in processed form. Related products available in the country are dietary supplements such as cannabidiol (CBD) oils and ointments or other cosmetics that absorb cannabidiol (CBD) through the skin. cannabidiol (CBD) oils are, however, only available on prescription.

Key players in the cannabidiol medicine market undertake this strategy to strengthen their product portfolios and offer customers diverse, technologically advanced, innovative products. Companies prominently adopt this strategy to expand their customer base. For instance, in 2025, British Cannabis expanded its product portfolio in the UK by launching a wider range of cannabidiol (CBD) edibles, including gummies and capsules, under its wellness brands. 

Key players in the industry are focusing on regional expansion to strengthen their market presence, tap into emerging consumer bases, and navigate evolving regulatory frameworks across different geographies. For instance, in July 2025, SOMAÍ, a leading EU-GMP certified and vertically integrated multi-country operator (MCO), expanded into Italian market through a partnership with Materia Medica Processing, one of Italy’s leading pharmaceutical cannabis companies, The company already has an established presence in markets such as Australia, the UK, and Germany, and is further planning expansion into Ireland, Poland, and Switzerland. Its entry into Italy marks another important milestone in its strategy to enhance global access to high-quality cannabis-based therapeutics.

Source Insights

On the basis of source, hemp-derived cannabidiol (CBD) dominated the market and generated 52.6% of the revenue in 2025, driven by favorable regulatory status, low tetrahydrocannabinol (THC) content, and wide acceptance across medical and wellness applications. Hemp-derived cannabidiol (CBD) is non-psychoactive and is legally permitted across most European countries, making it the preferred raw material for manufacturers and consumers. For instance, in February 2025, Sanity Group strengthened its hemp-based cannabidiol (CBD) portfolio across Europe by focusing on legally compliant, hemp-derived wellness and medical products. The company emphasized pharmaceutical-grade cannabidiol (CBD) extracted from industrial hemp and expanded its presence through pharmacy and retail distribution channels.

The Marijuana-derived cannabidiol (CBD) segment is expected to grow at the fastest CAGR over the forecast period, driven by the increasing legalization of medical cannabis across Europe and the rising demand for high-potency, therapeutically effective cannabinoid formulations. For instance, in February 2026, Aurora Cannabis Inc. announced the expansion of its medical cannabis portfolio in Europe, particularly in Germany and the UK, by supplying high-THC and balanced cannabidiol (CBD) cannabis formulations for patients through pharmacies and healthcare providers. 

Product Insights

The OTC cannabidiol (CBD) Products dominated the market segment with 71.6% of the revenue in 2025, driven by the widespread availability of non-prescription cannabidiol (CBD) formats such as oils, tinctures, capsules, topicals, and edibles. For instance, in June 2025, British Cannabis expanded its OTC cannabidiol (CBD) product portfolio in the UK by introducing a broader range of wellness-focused products, including cannabidiol (CBD) oils, capsules, and edibles under its consumer brands. This expansion was aimed at enhancing accessibility through retail and online channels, reflecting the strong demand for over-the-counter cannabidiol (CBD) products in the European market.

The Pharmaceutical-grade cannabidiol (CBD) (Rx formulations) segment is expected to grow at the fastest CAGR over the forecast period, due to the increasing adoption of clinically approved and prescription-based cannabinoid therapies. This growth is supported by rising clinical evidence validating the efficacy of cannabidiol (CBD) in treating neurological disorders, epilepsy, chronic pain, and other medical conditions. For instance, in May 2025, GW Pharmaceuticals (a subsidiary of Jazz Pharmaceuticals) continued to strengthen the presence of its prescription cannabidiol (CBD) drug Epidyolex across Europe, supported by growing clinical adoption and expanding treatment indications for rare epilepsy disorders such as Lennox-Gastaut syndrome and Dravet syndrome. 

Application Insight

The medical/therapeutic Use dominated the market segment with 38.5% of the revenue and is the fastest-growing segment. The growth is primarily driven by the increasing clinical validation of cannabidiol (CBD) in treating chronic conditions, including epilepsy, pain management, anxiety, and neurological disorders. For instance, in March 2025, Cantourage Group SE reported strong growth in its medical cannabis business across Europe, driven by increasing patient access and demand for cannabinoid-based therapies. 

The Personal Care & Cosmetics segment is expected to grow significantly. The growth is driven by rising consumer demand for natural, plant-based, and multifunctional skincare products. cannabidiol (CBD) is increasingly used in creams, serums, lotions, and balms due to its anti-inflammatory, antioxidant, and skin-soothing properties, making it effective for acne, aging, and sensitive skin conditions. For instance, in November 2025, the European Commission (Directorate-General for Health and Food Safety) released a scientific opinion and opened consultations regarding the use of cannabidiol (cannabidiol (CBD)) in cosmetic products, highlighting its growing adoption in skincare formulations such as creams, serums, and balms across Europe. 

Formulation Insights

The full-spectrum cannabidiol (CBD) segment dominated the market with the largest revenue share of 40.1%in 2025, driven by the ability to deliver the “entourage effect,” where multiple cannabinoids, terpenes, and flavonoids work synergistically to enhance therapeutic outcomes. This formulation is widely preferred in both medical and wellness applications because it offers higher efficacy compared to cannabidiol (CBD) isolate and broad-spectrum variants. For instance, in March 2025, Nordic Oil strengthened its product portfolio across Europe by expanding its range of full-spectrum cannabidiol (CBD) oils and wellness products, focusing on high-quality, terpene-rich formulations to enhance the entourage effect. 

The broad-spectrum cannabidiol (CBD) segment is the fastest-growing segment, driven by increasing consumer preference for THC-free products that still retain multiple beneficial cannabinoids and terpenes. This formulation appeals particularly to consumers seeking therapeutic benefits without any psychoactive effects or regulatory concerns associated with THC. The segment is also gaining traction in regions with stricter cannabis regulations, including parts of Europe, where THC limits are tightly controlled. For instance, in March 2025, Bedrocan introduced a high-cannabidiol (CBD) cannabis raw material (Bedrolina) at Vitafoods Europe, designed for use in nutraceutical and wellness formulations. The product contains high cannabidiol (CBD) content with less than 1% THC, making it suitable for developing broad-spectrum and low-THC cannabidiol (CBD) products aligned with European regulatory standards.

Distribution Channel

The e-commerce / Online Platforms dominated the market with over 31% share in 2025, driven by the rapid digitalization of retail and the ability of brands to directly reach consumers across borders. Online platforms offer convenience, wider product variety, transparent product information, and customer reviews, which are particularly important in the cannabidiol (CBD) market, where consumers seek education and trust before purchase. For instance, in June 2024, Formula Swiss expanded its digital footprint by launching new online stores in Sweden and Finland, enabling direct-to-consumer access to its certified organic cannabidiol (CBD) products across additional European markets. 

To learn more about this report, Download Free Sample Report

The Supermarkets/Hypermarkets segment is driven by increasing mainstream acceptance of cannabidiol (CBD) products and their gradual integration into traditional retail environments. Consumers prefer purchasing cannabidiol (CBD) products from trusted retail chains, where product authenticity, safety, and regulatory compliance are assured. The expansion of cannabidiol (CBD) into supermarket shelves also reflects the transition of cannabidiol (CBD) from niche wellness products to mass-market consumer goods. For instance, in May 2024, Goodrays expanded its cannabidiol (CBD)-infused drinks distribution across major UK retail chains, making its products available in supermarkets and large-format stores.

Country Insights

Germany cannabidiol market held the largest revenue share in 2025. The market is driven by an established regulatory framework, early legalization of medical cannabis, and a strong healthcare infrastructure. The country allows prescription-based access to cannabis through a wide pharmacy network, significantly boosting medical cannabidiol (CBD) adoption. Increasing acceptance of cannabis for both therapeutic and wellness applications, along with supportive reimbursement systems, has strengthened market penetration. Germany’s regulatory clarity and high consumer awareness continue to attract investments and product innovation, positioning it as the leading market in Europe.

The cannabidiol market in the UK is expected to grow at a considerable rate over the forecast period. The growth is driven by rising consumer awareness, expanding retail availability (including pharmacies, wellness stores, and e-commerce platforms), and increasing use of cannabidiol (CBD) in food supplements, cosmetics, and personal care products. The UK market benefits from strong private-sector participation and product diversification, especially in cannabidiol (CBD) oils, edibles, and beverages. Furthermore, evolving regulatory discussions around cannabidiol (CBD) product limits and novel food approvals are shaping the competitive landscape, while continued demand for wellness-oriented products is expected to sustain growth over the forecast period

Poland cannabidiol market is expected to grow significantly over the forecast period. The growth is driven by rising patient demand for medical cannabis, increasing awareness of cannabidiol’s therapeutic benefits, and gradual regulatory development. Although the market has experienced regulatory adjustments (such as restrictions on telemedicine prescriptions), it has demonstrated resilience with recovery in product demand and distribution through structured healthcare channels. Expanding access through pharmacies and improving regulatory clarity are expected to further support Poland’s long-term market expansion, making it a key growth hub in the European cannabidiol (CBD) landscape.

Key Cannabidiol Companies Insights

Several market players are focusing on initiatives, such as distribution partnerships and product innovation, to maintain their position in the market. For instance, in January 2026, Medios AG, a European specialty pharmaceutical company, entered the medical cannabis market through a strategic partnership with Bedrocan International, a Dutch manufacturer of pharmaceutical-grade cannabis. Under this agreement, Medios secured exclusive distribution rights across key European markets, including Germany, Spain, Belgium, Italy, and Austria, leveraging products sourced from EU-GMP-certified facilities.
The following are the leading companies in the Europe cannabidiol market. These companies collectively hold the largest market share and dictate industry trends. Financials, strategy maps & products of these Europe cannabidiol companies are analyzed to map the supply network.

Recent Developments

• In March 2026, GVB Biopharma reported record-breaking production and sales, highlighting the rapid scaling of the global cannabinoid supply chain. The company sold over 12,000 kg of CBD, CBG, and CBN isolates in a single month, equivalent to more than 1 billion 10 mg doses, while total sales for Q1 2026 exceeded 30,000 kg.

• In March 2026, Organigram Global Inc. pursued strategic expansion into Europe through acquisition-led growth initiatives, targeting Germany and other key markets to enhance product distribution and market penetration across the region. 

• In October 2025, Releaf expanded its operations into Germany to strengthen its presence in the European medical cannabis market. This move aimed to improve patient access and cross-border distribution of cannabis-based therapies, reflecting the growing trend of regional expansion among European cannabidiol (CBD) and medical cannabis companies. 

• In February 2025, Indena announced that it has secured European Pharmacopoeia Certificate of Eligibility (CEP) certification for its CBD extract, intended for both clinical and commercial applications. The CEP, issued by the European Directorate for the Quality of Medicines (EDQM), validates that the active substance meets stringent European Pharmacopoeia standards for quality and safety.

• In January 2024, PharmaCielo Ltd, a Canadian company, announced its strategic partnership with Benuvia, to manufacture cGMP Pharmaceutical-grade cannabidiol (CBD) Isolate and related products and introduce them into the global market, including Europe, Brazil, Australia and the U.S.

Europe Cannabidiol Market Report Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Europe cannabidiol market report based on source, product, application, formulation, distribution channel, and country:

• Source Outlook (Revenue, USD Million, 2021 - 2033)

  • Hemp-derived cannabidiol (CBD)

  • Marijuana derived cannabidiol (CBD)

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • OTC cannabidiol (CBD) Products

    • Cannabidiol (CBD) Oil & Tinctures (Drops)

    • Cannabidiol (CBD) Capsules

    • Topicals (Creams, Balms, Skincare)

    • Edibles (Gummies, Beverages, Functional Foods)

    • Vape Products

  • Pharmaceutical-grade cannabidiol (CBD) (Rx formulations)

    • Oral solutions (cannabidiol (CBD) Oils, Tinctures/Drops)

    • Capsules

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Medical / Therapeutic Use

  • Wellness & Lifestyle

  • Personal Care & Cosmetics

  • Food & Beverage

  • Others (Pet care, niche uses)

• Formulation Outlook (Revenue, USD Million, 2021 - 2033)

  • Full-spectrum cannabidiol (CBD)

  • Broad-spectrum cannabidiol (CBD)

  • Cannabidiol (CBD) Isolate

• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • E-commerce / Online Platforms

  • Retail Pharmacies

  • Specialty Stores (cannabidiol (CBD) stores, wellness shops)

  • Supermarkets/Hypermarkets

  • Hospitals & Clinics (Rx cannabidiol (CBD))

• Country Outlook (Revenue, USD Million, 2021 - 2033)

  • Europe

    • Germany

    • UK

    • Italy

    • France

    • Netherlands

    • Switzerland

    • Spain

    • Poland

    • Czech Republic

    • Croatia